# Inotek Pharmaceuticals Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inotek-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Lexington, US
- Website: www.inotekpharma.com
- Total disclosed funding: $92M
- Latest round: Series D (Jun 10, 2010)
- Investors on record: 10

## About

Founded in 1999 and based in Massachusetts, US, Inotek Pharmaceuticals Corporation  is a clinical-stage, publicly traded (ITEK) biopharmaceutical company focused on the discovery and development  of therapies to treat glaucoma and other diseases of the eye. In January 2018, Inotek Pharmaceuticals Corporation, a portfolio company of Care Capital, Devon Park Bioventures, MedImmune Ventures, Pitango Venture Capital, and RHO Capital Partners, merged with Rocket Pharmaceuticals. The combined company retained the Rocket Pharmaceuticals, Inc. name.

## Funding rounds

- Series D, Jun 10, 2010, $18M — Care Capital, Pitango, RHO, Devon Park Bioventures, SG Growth Capital, MedImmune Ventures
- Series C, Aug 23, 2007, $19M — Care Capital, Pitango, RHO, CDPQ, MedImmune Ventures, Hercules Capital, Mitsubishi UFJ Capital, Meditor Capital Management Limited
- Series B, Nov 17, 2005, $10M — Care Capital, Pitango, RHO, CDPQ, MedImmune Ventures
- Series B, Aug 30, 2005, $25M — Care Capital, Pitango, RHO, MedImmune Ventures
- Series A, Apr 13, 2004, $20M — Care Capital, RHO, MedImmune Ventures

## Investors

- Care Capital (https://capitalatlas.ai/funds/care-capital) — Series A, Series B, Series C, Series D
- RHO (https://capitalatlas.ai/funds/rho) — Series A, Series B, Series C, Series D
- MedImmune Ventures (https://capitalatlas.ai/funds/medimmune-ventures) — Series A, Series B, Series C, Series D
- Pitango (https://capitalatlas.ai/funds/pitango) — Series B, Series C, Series D
- CDPQ — Series B, Series C
- Hercules Capital (https://capitalatlas.ai/funds/hercules-capital) — Series C
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series C
- Meditor Capital Management Limited — Series C
- Devon Park Bioventures (https://capitalatlas.ai/funds/devon-park-bioventures) — Series D
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series D